Physician profile
Mark E Benesch
NPI 1932101292
$347.80
in general payments reported to CMS, 2019-2025
10 companies · $23.58 in 2025
The $23.58 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.13 · 2022: $88.62 · 2023: $77.90 · 2024: $62.57 · 2025: $23.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $80.86 | 2021-2023 | |
| Lilly USA, LLC | $60.48 | 2022-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $51.34 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $34.34 | 2022-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $28.95 | 2021-2023 | M-M-R II, Gardasil 9, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.18 | 2021-2023 | Jardiance |
| Phathom Pharmaceuticals, INC. | $23.58 | 2025 | Voquezna |
| Novo Nordisk INC | $15.55 | 2024 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $15.47 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Benesch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.